Tower Research Capital LLC (Trc) Metacrine, Inc. Transaction History

Tower Research Capital LLC (Trc)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.35 - $0.46 $8 - $11	24 Added 0.13%	18,413 $8,000
Q3 2022 Nov 10, 2022	BUY	$0.43 - $0.55 $5,786 - $7,401	13,457 Added 272.85%	18,389 $9,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.63 $4,479 - $7,839	-12,443 Reduced 71.61%	4,932 $2,000
Q1 2022 May 12, 2022	BUY	$0.43 - $0.7 $6,615 - $10,770	15,386 Added 773.55%	17,375 $11,000
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $1,354 - $8,108	-2,117 Reduced 51.56%	1,989 $1,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $3,064 - $4,508	1,174 Added 40.04%	4,106 $14,000
Q2 2021 Aug 16, 2021	BUY	$3.37 - $5.73 $5,580 - $9,488	1,656 Added 129.78%	2,932 $12,000
Q1 2021 May 17, 2021	SELL	$6.2 - $11.0 $7,322 - $12,991	-1,181 Reduced 48.07%	1,276 $8,000
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $19,041 - $28,058	2,457 New	2,457 $19,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.